Drug intelligence / Profile preview

siRNA targeting SATB2

Development stage
Preclinical
Lead developer
Weill Cornell Medicine
Modality
Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
Administration
Intravenous, Subcutaneous, Intrathecal, Intravitreal, Parenteral
01

Overview

siRNA targeting SATB2 refers to small interfering RNA molecules designed to silence the expression of the Special AT-rich sequence-binding protein 2 (SATB2). SATB2 is a transcription factor and chromatin remodeler that regulates gene expression in a tissue-specific manner. In the context of colorectal cancer (CRC), SATB2 is often lost during the progression from adenoma to carcinoma, and its loss is associated with an aggressive phenotype, chromosomal instability, and a pro-inflammatory immune microenvironment. Research using SATB2-targeting siRNA in cell lines like SW480 has demonstrated that reducing SATB2 levels promotes epithelial-mesenchymal transition and increases the expression of checkpoint genes like PD-1 and CTLA-4. While currently utilized primarily as a research tool to study tumor suppression and immune regulation, SATB2 modulation represents a potential area of interest in oncology and inflammatory bowel disease.

Other names
SATB2 siRNASATB-2 siRNASATB 2 siRNAsiRNA-mediated knockdown of SATB2
02

Targets

Special AT-rich sequence-binding protein 2 (SATB2) mRNA

Beyond the preview

Go deeper on siRNA targeting SATB2.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on siRNA targeting SATB2.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call